Trials / Unknown
UnknownNCT01924156
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Renal Cell Carcinoma: a Phase I/II Study
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma. Experimental recombinant adenovirus-transfected DC, which engineered to express MUC1 and Survivin are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the investigators plan to perform the clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | adenovirus-transfected DC + CIK | adenovirus-transfected DC vaccine plus CIK cells |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2013-08-16
- Last updated
- 2016-02-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01924156. Inclusion in this directory is not an endorsement.